Cargando…

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

This randomized, double-blind, double-dummy parallel study compared the anti-emetic efficacy and tolerability of the serotonin antagonist granisetron with prednisolone plus the dopamine D(2) antagonist metopimazine during nine cycles of moderately emetogenic chemotherapy. Chemotherapy naive women wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sigsgaard, T, Herrstedt, J, Andersen, L J, Havsteen, H, Langer, S W, Kjærbøl, A-G, Lund, H, Kjær, M, Dombernowsky, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362348/ https://www.ncbi.nlm.nih.gov/pubmed/10408847 http://dx.doi.org/10.1038/sj.bjc.6690372

Ejemplares similares

Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis.
por: Carmichael, J., et al.
Publicado: (1994)

Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy
por: Toda, Haruka, et al.
Publicado: (2017)

Pharmacokinetic study of metopimazine by oral route in children
por: Mallet, Eric, et al.
Publicado: (2015)

Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
por: de Wit, R., et al.
Publicado: (1998)

Metopimazine is primarily metabolized by a liver amidase in humans
por: Busby, Robert W., et al.
Publicado: (2021)

Cathodic adsorptive stripping voltammetry of an anti-emetic agent Granisetron in pharmaceutical formulation and biological matrix
por: Jain, Rajeev, et al.
Publicado: (2012)

Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial
por: Sun, Der Sheng, et al.
Publicado: (2023)

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
por: Gabrail, Nashat, et al.
Publicado: (2015)

Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial
por: Eghbali, Aziz, et al.
Publicado: (2023)

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy
por: de Wit, R, et al.
Publicado: (2001)

Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy.
por: Smith, D. B., et al.
Publicado: (1990)

Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy
por: Vardy, J, et al.
Publicado: (2006)

Postoperative nausea and vomiting prophylaxis: A comparative study of ondansetron, granisetron and granisetron and dexamethasone combination after modified radical mastectomy
por: Gupta, Pushplata, et al.
Publicado: (2014)

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study
por: Boccia, Ralph V., et al.
Publicado: (2010)

Granisetron Versus Dexamethasone in Prophylaxis of Nausea and Vomiting After Laparoscopic Cholecystectomy
por: Hessami, Mohammad Ali, et al.
Publicado: (2012)

Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
por: Hingmire, Sachin, et al.
Publicado: (2015)

In situ polymerization and FT-IR characterization of poly-glycine on pencil graphite electrode for sensitive determination of anti-emetic drug, granisetron in injections and human plasma
por: Ali, Marwa F. B., et al.
Publicado: (2019)

Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
por: Lee, So Rae, et al.
Publicado: (2020)

Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study
por: Wakasugi, Yoshinori, et al.
Publicado: (2019)

Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK
por: Campos, Mauro, et al.
Publicado: (2011)

Emetics
Publicado: (1892)

Palonosetron, Ondansetron, and Granisetron for antiemetic prophylaxis of postoperative nausea and vomiting - A comparative evaluation
por: Gupta, Kumkum, et al.
Publicado: (2014)

Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)
por: Shimizu, Hisanori, et al.
Publicado: (2018)

Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation
por: Cabanillas Stanchi, Karin Melanie, et al.
Publicado: (2020)

Emetics and Nauseants
Publicado: (1873)

Alum as an Emetic
Publicado: (1854)

Apomorphia as an Emetic
Publicado: (1885)

Alum as an Emetic
Publicado: (1854)

Retraction notice to "A Randomized, Double-Blind Comparison of Granisetron Alone and Combined with Dexamethasone for Post–Laparoscopic Cholecystectomy Emetic Symptoms": [CTR 64/8 (2003) 514- 521]
por: Fujii, Yoshitaka, et al.
Publicado: (2018)

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial
por: Raftopoulos, Harry, et al.
Publicado: (2014)

Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
por: Navari, Rudolph M., et al.
Publicado: (2018)

Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew (Cryptotis parva)
por: Belkacemi, Louiza, et al.
Publicado: (2022)

Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies
por: Cabanillas Stanchi, Karin Melanie, et al.
Publicado: (2019)

Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group.
por: Riviere, A.
Publicado: (1994)

Poisoning by Tartar Emetic
por: McConnell, J. F. P.
Publicado: (1876)

Poisoning by Tartar Emetic
Publicado: (1876)

On Emetics in Diabetes Mellitus
por: Walker, J. R.
Publicado: (1814)

Tarter-Emetic in Pneumonia
Publicado: (1870)

Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
por: Chasen, Martin, et al.
Publicado: (2016)

The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
por: Eghbali, Aziz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fgq87d76vpbe1f4cc9imgithgp